Platelet interactions with heparin binding growth factor and fibronectin.

Area of Science:

• Biomaterials Science
• Vascular Surgery
• Hemostasis and Thrombosis

Background:

• Vascular graft biocompatibility is crucial for preventing thrombosis.
• Fibronectin (Fn) and heparin binding growth factors (HBGF) are key proteins involved in cell adhesion and signaling.
• Complexes of Fn/heparin/HBGF/heparin (FHHH) can be applied to vascular grafts to enhance their performance.

Purpose of the Study:

• To investigate the impact of Fn, HBGF, and FHHH complexes on platelet adhesion and aggregation on expanded polytetrafluoroethylene (PTFE) vascular grafts.
• To compare the effects of Fn and FHHH treatments on platelet deposition in a canine aortoiliac model.

Main Methods:

• Expanded PTFE grafts were treated with Fn or FHHH, or left untreated.
• Grafts were implanted into canine aortoiliac systems, with each dog serving as its own control.
• Autologous radiolabeled platelets were used to quantify platelet deposition via gamma counting and planimetry.

Main Results:

• FHHH and Fn-treated grafts showed significantly higher platelet radioactivity compared to untreated PTFE grafts when normalized to the iliac artery.
• FHHH treated grafts exhibited 27 times more radioactivity per mm², Fn treated grafts 12 times more, and untreated grafts 4 times more.
• In vitro studies demonstrated that neither Fn nor HBGF alone induced platelet aggregation.

Conclusions:

• Fn and HBGF contribute to increased platelet adhesion on vascular grafts.
• These proteins promote platelet adhesion independently of inducing platelet aggregation.
• The findings suggest potential for modulating graft thrombogenicity through targeted protein application.